Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Double Helix

Gilead Sciences

Gilead’s ulcerative colitis antibody flunks trial

Halts trial early as preliminary data shows no evidence of efficacy

- PMLiVE

Adult learning theory

Practical benefits for optimum patient outcomes

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

GSK throws gauntlet down to Merck with shingles vaccine data

Shingrix trial reported ninety per cent efficacy in elderly patients who do not respond well to Zostavax

Sanofi reception

Sanofi trumpets new IGlarLixi data after regulatory delay

Reports that the combination drug is more effective at controlling glucose than Lantus alone

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

- PMLiVE

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

Blue Latitude Health

- PMLiVE

Vectura’s Flutiform flunks phase III COPD test

But new AirFluSal data demonstrates superior patient adherence over GSK’s Seretide/Advair

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links